Abstract
This review summarizes the reported molecular mechanisms underlying the antileukemic property of Sesquiterpene Lactones (SLs). This systematic review was registered in the PROSPERO database and conducted following the PRISMA Statements. The MeSH terms, Sesquiterpenes, Lactones and Leukemia were used in four databases (Pubmed, Web of Science, Scopus and Bireme). There were 281 studies selected, but after exclusions, due to replication (n = 172) or not following PECOS criteria (n = 24), 148 studies remained. Of the 148 articles, only 22 were submitted to quality assessment and were scored in high level if more than two techniques, to elucidate antileukemic properties, were described, and then data were extracted. The studies mostly used human leukemia cell lines including primary and established cells, with or without chemotherapy resistance. The SLs used were obtained principally from plants. The antileukemic properties of SLs were extracted from 22 high level studies. They included cell death induction, mainly by apoptosis, as well as cell differentiation, cell cycle disruption, leukemia cancer stem cell growth inhibition and NF-κB pathway inhibition; the latter is a promising therapeutic target for lymphoid malignancies. We concluded that, in spite of the necessity of better toxicological profile characterization of SLs, the antileukemic properties of these compounds support the proposal that the SLs are promising candidates for the treatment of leukemia.
Keywords: Natural products, sesquiterpene lactones, leukemia, apoptosis, differentiation, cell cycle, cancer stem cell, NF-κB.
Anti-Cancer Agents in Medicinal Chemistry
Title:Antileukemic Properties of Sesquiterpene Lactones: A Systematic Review
Volume: 18 Issue: 3
Author(s): Elaine da Silva Castro, Livia Azeredo Alves Antunes, Jonathas Felipe Revoredo Lobo, Norman Arthur Ratcliffe, Ricardo Moreira Borges, Leandro Rocha, Patricia Burth and Lidia Maria Fonte Amorim*
Affiliation:
- Molecular and Cellular Biology Department, Biology Institute, Fluminense Federal University, Niteroi,Brazil
Keywords: Natural products, sesquiterpene lactones, leukemia, apoptosis, differentiation, cell cycle, cancer stem cell, NF-κB.
Abstract: This review summarizes the reported molecular mechanisms underlying the antileukemic property of Sesquiterpene Lactones (SLs). This systematic review was registered in the PROSPERO database and conducted following the PRISMA Statements. The MeSH terms, Sesquiterpenes, Lactones and Leukemia were used in four databases (Pubmed, Web of Science, Scopus and Bireme). There were 281 studies selected, but after exclusions, due to replication (n = 172) or not following PECOS criteria (n = 24), 148 studies remained. Of the 148 articles, only 22 were submitted to quality assessment and were scored in high level if more than two techniques, to elucidate antileukemic properties, were described, and then data were extracted. The studies mostly used human leukemia cell lines including primary and established cells, with or without chemotherapy resistance. The SLs used were obtained principally from plants. The antileukemic properties of SLs were extracted from 22 high level studies. They included cell death induction, mainly by apoptosis, as well as cell differentiation, cell cycle disruption, leukemia cancer stem cell growth inhibition and NF-κB pathway inhibition; the latter is a promising therapeutic target for lymphoid malignancies. We concluded that, in spite of the necessity of better toxicological profile characterization of SLs, the antileukemic properties of these compounds support the proposal that the SLs are promising candidates for the treatment of leukemia.
Export Options
About this article
Cite this article as:
da Silva Castro Elaine , Alves Antunes Azeredo Livia , Revoredo Lobo Felipe Jonathas , Ratcliffe Arthur Norman , Borges Moreira Ricardo , Rocha Leandro , Burth Patricia and Fonte Amorim Maria Lidia *, Antileukemic Properties of Sesquiterpene Lactones: A Systematic Review, Anti-Cancer Agents in Medicinal Chemistry 2018; 18 (3) . https://dx.doi.org/10.2174/1871520617666170918130126
DOI https://dx.doi.org/10.2174/1871520617666170918130126 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
CYLD-Mediated Signaling and Diseases
Current Drug Targets Apoptosis Induced by Topoisomerase Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Long Non-coding RNA and microRNAs as Novel Potential Biomarker and Therapeutic Target in the Treatment of Gastrointestinal Cancers
Current Pharmaceutical Design Feasibility of Increased Navy Bean Powder Consumption for Primary and Secondary Colorectal Cancer Prevention
Current Nutrition & Food Science Cancer Therapy-Induced Residual Bone Marrow Injury: Mechanisms of Induction and Implication for Therapy
Current Cancer Therapy Reviews Lipid Microparticles for Oral Bioavailability Enhancement
Recent Patents on Nanomedicine Drug Resistance of Enzalutamide in CRPC
Current Drug Targets Novel Mechanistic Insights into the Anti-cancer Mode of Arsenic Trioxide
Current Cancer Drug Targets Pre-B Cell Colony Enhancing Factor/NAMPT/Visfatin in Inflammation and Obesity- Related Disorders
Current Pharmaceutical Design Finding the Smoking Gun: Protein Tyrosine Phosphatases as Tools and Targets of Unicellular Microorganisms and Viruses
Current Medicinal Chemistry Targeting Metallothionein for Prognosis and Treatment of Breast Cancer
Recent Patents on Anti-Cancer Drug Discovery Molecularly Targeted Therapy for Gastrointestinal Cancer
Current Cancer Drug Targets The Effect of Bitter Melon (Momordica charantia) Extract on the Uptake of <sup>99m</sup>Tc Labeled Paclitaxel: In Vitro Monitoring in Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry The Design of Multifunctional Microbubbles for Ultrasound Image-Guided Cancer Therapy
Current Topics in Medicinal Chemistry Recent Advances in Herbal Nanomedicines for Cancer Treatment
Current Molecular Pharmacology Endocannabinoid System: A Multi-Facet Therapeutic Target
Current Clinical Pharmacology Circulating Biomarkers for Tumor Angiogenesis: Where Are We?
Current Medicinal Chemistry IMPMD: An Integrated Method for Predicting Potential Associations Between miRNAs and Diseases
Current Genomics Discovery of Hybrid Purine-quinoline Molecules and Their Cytotoxic Evaluation
Letters in Drug Design & Discovery Antimicrobial Activity of Royal Jelly
Anti-Infective Agents